Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amicus Therapeutics Inc.

www.amicusrx.com

Latest From Amicus Therapeutics Inc.

Pipeline Watch: Topline Phase III Results For Caplacizumab, Relugolix, Iclaprim

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Pipeline Watch: Phase III Readouts For ADV7103, Pembrolizumab, Upadacitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Amicus Drops Epidermolysis Bullosa Candidate Following Phase III Failure

CEO Crowley points to the need to focus on a pair of Fabry candidates, including the pending NDA for migalastat, and notes that other companies have reached Phase III in EB.

Clinical Trials Rare Diseases

Pipeline Watch: Phase III Progress With Semaglutide, Sotagliflozin

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Amicus Therapeutics Inc.
  • Senior Management
  • John F Crowley, Chmn. & CEO
    Chip D Baird, CFO
    Michael C Diem, MD, SVP, Bus. & Corp. Dev.
    Hung Do, PhD, CSO
    Jay A Barth, MD, CMO
    Bradley L Campbell, Pres. & COO
    Daphne Quimi, SVP, Finance and Admin.
    David Allsop, SVP, International
    Enrique Dilone, PhD, SVP, Technical Ops.
    Jeffrey Castrelli, PhD, SVP, Program Management & Portfolio Planning
  • Contact Info
  • Amicus Therapeutics Inc.
    Phone: (609) 662-2000
    1 Cedar Brook Dr.
    Cranbury, NJ 08512
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register